Curis Inc
CRIS1.030USD
+0.119+13.11%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
13.12MMarket Cap
LossP/E TTM
More Details of Curis Inc Company
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Curis Inc Info
Ticker SymbolCRIS
Company nameCuris Inc
IPO dateAug 01, 2000
CEODentzer (James E)
Number of employees33
Security typeOrdinary Share
Fiscal year-endAug 01
Address128 Spring Street
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone16175036500
Websitehttps://www.curis.com/
Ticker SymbolCRIS
IPO dateAug 01, 2000
CEODentzer (James E)
Company Executives of Curis Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+2310.00%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+4255.00%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+2310.00%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+4255.00%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.78%
Armistice Capital LLC
7.57%
Satterfield (Thomas A Jr)
6.86%
Citi Investment Research (US)
4.49%
M28 Capital Management LP
4.03%
Other
68.27%
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.78%
Armistice Capital LLC
7.57%
Satterfield (Thomas A Jr)
6.86%
Citi Investment Research (US)
4.49%
M28 Capital Management LP
4.03%
Other
68.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.27%
Hedge Fund
9.74%
Individual Investor
6.99%
Research Firm
4.70%
Investment Advisor/Hedge Fund
1.84%
Other
57.45%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
83
4.63M
39.24%
--
2025Q3
85
4.63M
39.84%
+335.60K
2025Q2
95
4.29M
47.96%
-381.52K
2025Q1
104
4.67M
35.08%
+1.00M
2024Q4
110
3.21M
29.04%
+1.19M
2024Q3
121
2.02M
47.43%
-296.29K
2024Q2
144
2.32M
48.36%
+147.50K
2024Q1
219
2.10M
55.49%
-1.17M
2023Q4
242
2.06M
62.43%
-75.74K
2023Q3
258
2.13M
59.12%
+333.55K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bleichroeder LP
1.14M
8.78%
+100.00K
+9.66%
Sep 30, 2025
Armistice Capital LLC
978.19K
7.57%
+78.27K
+8.70%
Sep 30, 2025
Satterfield (Thomas A Jr)
886.71K
6.86%
+274.49K
+44.84%
Mar 31, 2025
Citi Investment Research (US)
581.12K
4.49%
+489.25K
+532.53%
Sep 30, 2025
M28 Capital Management LP
521.06K
4.03%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
367.62K
2.84%
+64.43K
+21.25%
Sep 30, 2025
CM Management, LLC
325.00K
2.51%
+105.00K
+47.73%
Sep 30, 2025
Renaissance Technologies LLC
175.51K
1.36%
+75.04K
+74.69%
Sep 30, 2025
Geode Capital Management, L.L.C.
94.67K
0.73%
+9.36K
+10.98%
Sep 30, 2025
Focused Wealth Management, Inc.
79.20K
0.61%
+20.00K
+33.77%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
